Edition:
United States

Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

3.36USD
2:09pm EST
Change (% chg)

$0.08 (+2.44%)
Prev Close
$3.28
Open
$3.32
Day's High
$3.41
Day's Low
$3.27
Volume
331,012
Avg. Vol
292,471
52-wk High
$4.47
52-wk Low
$2.81

Chart for

About

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company's lead product, Vascepa (icosapent ethyl) capsule,... (more)

Overall

Beta: 0.60
Market Cap(Mil.): $888.48
Shares Outstanding(Mil.): 270.88
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 196.13 16.04
EPS (TTM): -- -- --
ROI: -- -11.69 35.70
ROE: -- -36.44 15.40

BRIEF-Amarin reports Q3 loss per share $0.04

* Amarin reports third quarter 2017 financial results and provides update on operations

Nov 01 2017

BRIEF-Amarin and HLS Therapeutics announce agreement to commercialize Vascepa in Canada

* Amarin and HLS Therapeutics announce agreement to commercialize Vascepa in Canada

Sep 25 2017

BRIEF-Amarin names Mark Salyer chief commercial officer

* Amarin appoints Mark W. Salyer to new position of chief commercial officer

Sep 13 2017

BRIEF-Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned

* Amarin's reduce-it cardiovascular outcomes study of Vascepa to continue as planned at recommendation of independent data monitoring committee

Aug 14 2017

BRIEF-Amarin reports Q2 loss per share $0.05

* Amarin reports second quarter 2017 financial results and provides update on operations

Aug 02 2017

Competitors

Earnings vs. Estimates